Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24363687 | 0.86 | GPR3 (0.52) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL19449135 | 0.85 | NR1I3 (0.52) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL16202757 | 0.83 | L3MBTL1 (0.63) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL12136806 | 0.83 | NR1I3 (0.62) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL18503935 | 0.82 | NR1I3 (0.50) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL15860237 | 0.82 | ALDH1A1 (0.69) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL28159697 | 0.82 | KMT2A (0.50) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL18503937 | 0.82 | KMT2A (0.50) | KMT2ANR1I3NPC1RAB9AALDH1A1 | |
| SCHEMBL729919 | 0.81 | NUDT1 (0.61) | KMT2AALDH1A1TSHRKDM4EL3MBTL1 | |
| SCHEMBL30537037 | 0.81 | NUDT1 (0.61) | KMT2AALDH1A1TSHRKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3757100-B1 | TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS | NOVALED GMBH (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-11530201-B2 | Triazine compounds substituted with bulky groups | NOVALED GMBH (DE) | 2022-12-20 | — | — | US | disclosed |
| EP-3757100-A1 | TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS | Novaled GmbH (DE) | 2020-12-30 | — | — | EP | disclosed |
| US-20200361916-A1 | Triazine Compounds substituted with Bulky Groups | SAMSUNG SDI CO. LTD. (KR) | 2020-11-19 | — | — | US | disclosed |
| EP-3502106-B1 | TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS | NOVALED GMBH (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-3503240-A1 | ORGANIC SEMICONDUCTOR LAYER | Novaled GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530201-B2 | Triazine compounds substituted with bulky groups | POU5F1, POU2F1, IKZF2 | KMT2A 465/4885NR1I3 2291/4885NPC1 3519/4885 |
| US-20200361916-A1 | Triazine Compounds substituted with Bulky Groups | POU5F1, POU2F1, IKZF2 | KMT2A 465/4885NR1I3 2291/4885NPC1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.